retatrutide.md Blog

Retatrutide targets three hormone receptors instead of two, producing the largest weight loss seen in clinical trials. Here's how it compares to tirzepatide and what's ahead.

retatrutide.md provides a 2026 update on retatrutide clinical trials — phase 3 progress, expected approval timeline, and how results compare to tirzepatide.

retatrutide.md reviews the known side effects from phase 2 trials and what patients should watch for as phase 3 data emerges.

retatrutide.md explains the science behind triple agonist medications — what each receptor does and why targeting three pathways produces unprecedented weight loss.

retatrutide.md explores how retatrutide's unprecedented liver fat reduction could change treatment for the 100+ million Americans with fatty liver disease.

retatrutide.md previews every major obesity medication in development — from triple agonists to oral GLP-1s to amylin combinations.

Lilly plans to file with the FDA in Q1 2027, which puts the earliest realistic decision in 2028. Here is every Phase 3 readout so far and what still has to happen first.

TRIUMPH tested retatrutide against two obesity complications directly: it cut the apnea-hypopnea index by up to 36.1 events per hour and reduced WOMAC knee pain by up to 4.5 points. Here is the data, and what is still missing.

TRIUMPH-1 averaged 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg at 80 weeks. Here is every dose and trial number, how it compares to Wegovy and Zepbound, and what the averages hide.

No. Retatrutide is unapproved everywhere, the FDA says it cannot be compounded, and tests of similar gray-market GLP-1 vials found 7.7% purity and endotoxin in every sample.

Retatrutide hit three receptors and 28.3% weight loss at 80 weeks in Phase 3. Semaglutide hit one receptor and 14.9% in STEP 1. Only one is approved today.

Retatrutide is investigational, so it has no price or coverage yet. Lilly plans an FDA filing in Q1 2027. Here is what the approved rivals cost today.

Phase 2 tested 1, 4, 8 and 12 mg weekly (up to 24.2% weight loss at 48 weeks). Phase 3 TRIUMPH uses 4, 9 and 12 mg from a 2 mg start. Not dosing advice.

Retatrutide's only published DXA substudy showed fat mass fell up to 26.1%, with a lean-loss share like other obesity drugs. No TRIUMPH body data yet.

Retatrutide cut A1C by up to 2.0% in type 2 diabetes trials, and 72% with prediabetes reached normal A1C in phase 2. What the trials show on blood sugar.

Retatrutide's heart trial, TRIUMPH-Outcomes, enrolls about 10,000 adults and runs to 2029. What TRIUMPH-3 and phase 2 showed on blood pressure and lipids.

No retatrutide trial has measured body weight off the drug. In comparable GLP-1 trials, about 60% of the weight lost returns within a year of stopping.

Retatrutide trials have not reported hair loss as a common side effect. Wegovy and Zepbound labels list it in 3% to 6% of users, tied to rapid weight loss.

Dysesthesia (tingling, burning or touch-sensitive skin) hit 5% to 21% of people on retatrutide in phase 3 trials vs about 1% on placebo. What is known.

Retatrutide cut urine albumin 28% to 37% vs placebo in phase 2 trials and raised eGFR in obesity. Here is what that means and what kidney trials will show.

No study has tested alcohol with retatrutide. Early trials excluded drinkers above 14 or 21 units a week. Here is what GI, blood sugar and pancreas risks mean.

Retatrutide has no pregnancy data and no approved label as of October 2026. See what the trials excluded and what related drug labels and studies say.

A 46-person retatrutide birth control pill study ended in July 2024 with no public results. Here is what related drug labels say about backup methods.

No trial has tested microdosing retatrutide. The lowest studied doses were 0.5 mg and 1 mg weekly, and 0.5 mg did not beat placebo. See the evidence.

In pooled trials, retatrutide lowered LDL by 13.10 mg/dL, triglycerides by 40.90 mg/dL, and systolic blood pressure by 6.79 mmHg. It is not FDA approved.

Retatrutide has a half-life of about 6 days in a phase 1b trial, so most of it clears in about 30 days. It is not FDA approved and has no official washout.

In trials, retatrutide cut weight and blood sugar within 12 weeks. The 12 mg group lost 17.5% by week 24 and 25.0% by week 80 (ITT). Here is the time course.

Not legally yet. Retatrutide is investigational, Lilly plans to file in Q1 2027, and Phase 3 trials excluded anyone on a weight-loss drug in the prior 90 days.

Phase 2 trials logged 3 pancreatitis and 2 gallbladder inflammation cases in 457 retatrutide patients, none on placebo. What the data and GLP-1 labels show.